Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia

Leukemia Research

Volumn 37, Issue 7, 2013, Pages 765-768

  Qian, Jun ^a   Lin, Jiang ^a   Qian, Wei ^a   Ma, Ji chun ^a   Qian, Si xuan ^b   Li, Yun ^a   Yang, Jing ^a   Li, Jian yong ^b   Wang, Cui zhu ^a   Chai, Hai yan ^a   Chen, Xing xing ^a   Deng, Zhao qun ^a  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; MicroRNA; MiR 378

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; HEMOGLOBIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MICRORNA; MICRORNA 378; NUCLEOPHOSMIN; SMALL NUCLEAR RIBONUCLEOPROTEIN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; C EBPA GENE; C KIT GENE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CHROMOSOME TRANSLOCATION 8; CONTROLLED STUDY; CRYOPRESERVATION; DNMT3A GENE; FEMALE; FLT3 GENE; GENE MUTATION; GENE OVEREXPRESSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IDH1 GENE; IDH2 GENE; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NPM1 GENE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; U2AF1 GENE; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84878478179     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.03.014     Document Type: Article

References (35)

1. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
2. Chen J., Odenike O., Rowley J.D. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010, 10:23-36.
3. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
4. Zhao Y., Samal E., Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436:214-220.
5. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65:6029-6033.
6. Chen Y., Stallings R.L. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007, 67:976-983.
7. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005, 102:13944-13949.
8. Costinean S., Zanesi N., Pekarsky Y., Tili E., Volinia S., Heerema N., et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006, 103:7024-7029.
9. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
10. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
11. Landgraf P., Rusu M., Sheridan R., Sewer A., Iovino N., Aravin A., et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129:1401-1414.
12. Tenen D.G. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003, 3:89-101.
13. Marcucci G., Radmacher M.D., Maharry K., Mrózek K., Ruppert A.S., Paschka P., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1919-1928.
14. Garzon R., Heaphy C.E., Havelange V., Fabbri M., Volinia S., Tsao T., et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331-5341.
15. Lee D.Y., Deng Z., Wang C.H., Yang B.B. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 2007, 104:20350-20355.
16. Chen L.T., Xu S.D., Xu H., Zhang J.F., Ning J.F., Wang S.F. MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. Med Oncol 2012, 29:1673-1680.
17. Redova M., Poprach A., Nekvindova J., Iliev R., Radova L., Lakomy R., et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 2012, 10:55.
18. Liu H., Zhu L., Liu B., Yang L., Meng X., Zhang W., et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 2012, 316:196-203.
19. Imig J., Motsch N., Zhu J.Y., Barth S., Okoniewski M., Reineke T., et al. microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res 2011, 39:1880-1893.
20. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
21. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
22. Lo Coco F., Foa R. Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia. Eur J Haematol 1995, 55:1-9.
23. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
24. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
25. Szankasi P., Jama M., Bahler D.W. A new DNA-based test for detection of nucleophosmin exon 12 mutations by capillary electrophoresis. J Mol Diagn 2008, 10:236-241.
26. Lin J., Yao D.M., Qian J., Chen Q., Qian W., Li Y., et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2011, 6:e26906.
27. Lin J., Yao D.M., Qian J., Chen Q., Qian W., Li Y., et al. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 2012, 91:519-525.
28. Votavova H., Grmanova M., Dostalova Merkerova M., Belickova M., Vasikova A., Neuwirtova R., et al. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J Hematol Oncol 2011, 4:1.
29. Dostalova Merkerova M., Krejcik Z., Votavova H., Belickova M., Vasikova A., Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011, 19:313-319.
30. Marcucci G., Maharry K., Radmacher M.D., Mrózek K., Vukosavljevic T., Paschka P., et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008, 26:5078-5087.
31. Takeshita A., Shinjo K., Naito K., Ohnishi K., Higuchi M., Ohno R. Erythropoietin receptor in myelodysplastic syndrome and leukemia. Leuk Lymphoma 2002, 43:261-264.
32. Takeshita A., Shinjo K., Higuchi M., Miyawaki S., Takemoto Y., Kishimoto Y., et al. Quantitative expression of erythropoietin receptor (EPO-R) on acute leukaemia cells: relationships between the amount of EPO-R and CD phenotypes, in vitro proliferative response, the amount of other cytokine receptors and clinical prognosis, Japan Adult Leukaemia Study Group. Br J Haematol 2000, 108:55-63.
33. Scapoli L., Palmieri A., Lo Muzio L., Pezzetti F., Rubini C., Girardi A., et al. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol 2010, 23:1229-1234.
34. Sand M., Skrygan M., Sand D., Georgas D., Hahn S., Gambichler T., et al. Expression of microRNAs in basal cell carcinoma. Br J Dermatol 2012, 167:847-855.
35. Faltejskova P., Svoboda M., Srutova K., Mlcochova J., Besse A., Nekvindova J., et al. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 2012, 16:2655-2666.